Company / Working Capital
Cue Biopharma, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$23.5M
FY2025
5-year range
$11.4M / $65.6M
FY2021-FY2025
Trend
+105.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital returned to growth in FY2025 after 2 years of decline, reaching $23M.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of -19.9%.
Declined from $34M to $23M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -29.0%
- 5-Year CAGR
- -19.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.9%, indicating a declining trend.
- In FY2025, working capital increased 105.2% year-over-year.
- Peak working capital was recorded in FY2020.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.5M | +105.2% |
| FY2024 | $11.4M | -66.7% |
| FY2023 | $34.4M | -47.6% |
| FY2022 | $65.6M | +17.9% |
| FY2021 | $55.7M | -21.8% |
| FY2020 | $71.2M | +44.2% |
| FY2019 | $49.4M | +43.5% |
| FY2018 | $34.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026